5-HTP vs Placebo: What Controlled Trials Show (2026)

The gold standard for testing whether a supplement actually works is a randomized, placebo-controlled trial. Here’s what happens when 5-HTP has been tested head-to-head against placebo, and how to interpret those results honestly.

Found this useful? Send it to someone who needs it.

This article is for educational purposes and is not medical advice. 5-HTP affects serotonin, the same system targeted by antidepressants, triptans, and several other prescription drugs. Talk to a doctor or pharmacist before starting 5-HTP, especially if you take any prescription medication, are pregnant or breastfeeding, or have an existing health condition. This post may contain affiliate links; we may earn a commission at no extra cost to you.

What ‘Better Than Placebo’ Actually Means

In a placebo-controlled trial, neither participants nor researchers know who is getting the real supplement versus an inactive look-alike. If the 5-HTP group shows statistically significant improvement over the placebo group, that’s evidence of a real effect beyond expectation or natural symptom fluctuation.

That design is also where most of the 5-HTP record falls down. When a Cochrane review team screened the published depression literature against standard quality criteria, it located 108 trials and found only two that qualified, covering 64 patients between them[1].

The pooled result from those two did favour 5-HTP and tryptophan over placebo (Peto odds ratio 4.10, 95% confidence interval 1.28 to 13.15), but the reviewers judged the evidence too weak to be conclusive, and noted that alternatives with proven efficacy and safety already exist[1]. A 2020 meta-analysis arrived at a similar structural complaint from the other direction: of the 13 investigations it reviewed, few included a placebo group at all[2].

Mood Outcomes vs Placebo

The headline numbers in the 5-HTP mood literature are not modest. A 2020 systematic review and meta-analysis pooled seven investigations and reported a depression remission rate of 0.65 (95% confidence interval 0.55 to 0.78), alongside a large effect on questionnaire scores (Hedges g of 1.11, 95% confidence interval 0.53 to 1.69)[2]. The catch sits in the same paper. Heterogeneity was high, and the formal risk-of-bias assessment described the underlying studies as relatively weak, specifically because few of them included placebo groups[2].

A large average effect drawn mostly from uncontrolled studies is not the same claim as a large effect over placebo, and that distinction is the entire subject of this page.

Where 5-HTP has been tested against an active drug instead of a placebo it has held up reasonably well: a randomised double-blind trial in 60 patients with a first depressive episode found L-5-HTP and fluoxetine produced nearly equal reductions in Hamilton scores over eight weeks, with response rates of 73.3% and 80% respectively[3]. That trial had no placebo arm, so it speaks to how 5-HTP compares with fluoxetine, not to whether either separated from placebo.

NatureWise 5-HTP 200mg Supplement from Griffonia Seeds with Cofactor Vitamin B6 – Mood S
NatureWise 5-HTP 200mg Supplement from Griffonia Seeds with Cofactor Vitamin B6 - Mood S

States the Griffonia simplicifolia seed source explicitly, which is where commercial 5-HTP comes from generally, and adds B6 as the cofactor. At 200 mg it is a full-strength capsule rather than a starting one.

Capsules200 mg60 count
Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.

The Largest Modern Placebo-Controlled Trial

The biggest and most rigorous placebo-controlled test of 5-HTP to date was not a depression trial. In 2022, a multicentre team across 13 Belgian hospitals randomised 166 patients who had inflammatory bowel disease in remission but were still experiencing fatigue, giving them 100 mg of oral 5-HTP or placebo twice daily in a crossover design across two consecutive 8-week periods[4].

The supplement did what it is supposed to do biochemically. Serum 5-HTP rose by an estimated 52.66 ng/mL and serotonin by 3.0 ng/mL relative to placebo, both statistically significant[4]. The clinical outcomes did not follow. The proportion of patients reaching a 20% or greater reduction in fatigue was 37.6% on placebo and 35.6% on 5-HTP. Depression, anxiety and stress scores were likewise no different between the two arms[4].

Confirmed target engagement with no separation from placebo is the most informative single result in the modern literature. It rules out the easy explanation that the supplement simply was not absorbed, and it carries more weight than a stack of small positive studies from the era the Cochrane reviewers declined to pool. It is also worth noting what that trial measured: fatigue in a gastroenterology population, not depression in a psychiatric one.

The Placebo Response Problem in Mood Trials

Mood and depression trials are notorious for large placebo responses, meaning the inactive group often improves substantially just from trial participation, attention, and expectation. This makes it harder for any active treatment, 5-HTP included, to show a dramatically larger effect, and is a limitation that applies to psychiatric drug trials broadly, not just supplements. The 2022 crossover trial above is a concrete illustration: 37.6% of the patients taking an inactive capsule still reached the threshold for meaningful improvement[4]. Publication bias compounds the problem, because trials that find nothing are less likely to reach print in the first place[5].

Appetite and Satiety Outcomes vs Placebo

Appetite is where the placebo-controlled record is more consistent, partly because the endpoints are behavioural rather than self-reported mood. A 1989 double-blind crossover study gave 19 obese women 8 mg/kg/day of 5-HTP or placebo for five weeks with no dietary restrictions, and recorded anorexia-related symptoms, decreased food intake and weight loss[6]. That same trial found no change in mood state, which is a useful reminder that the appetite and mood literatures do not automatically vouch for each other[6].

A 1992 trial in the American Journal of Clinical Nutrition randomised 20 obese patients to 900 mg/day of 5-HTP or placebo across two consecutive six-week periods, with no diet prescribed in the first and a reduced-energy diet recommended in the second. Significant weight loss appeared in both periods, alongside a reduction in carbohydrate intake and a consistent presence of early satiety[7]. A 2009 randomised, double-blind, placebo-controlled trial in 27 overweight women, using a sublingual plant-extract spray containing 5-HTP rather than capsules, likewise found significantly greater satiety than placebo over eight weeks[8].

Jarrow 5-HTP 100 mg Capsules, Serotonin Precursor, 60 Count
Jarrow 5-HTP 100 mg Capsules, Serotonin Precursor, 60 Count

Plain 100 mg capsules at a middle-of-the-road count. Nothing else added, which makes it a clean comparison against the B6 and time-release versions stocked alongside it.

Capsules100 mg60 count
Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.

Dose Is Doing a Lot of Work in These Results

Read the doses in those appetite trials against what is actually on a shop shelf. The positive studies used 900 mg/day[7] and 8 mg/kg/day[6], which for a 70 kg adult works out to roughly 560 mg/day. Retail capsules are commonly 50 mg, 100 mg and 200 mg.

The one modern randomised trial run at a realistic retail dose points the other way on intake. An 8-week study randomised 48 exercise-trained adults to either 100 mg of 5-HTP daily or a maltodextrin placebo, and found no change in total energy intake or in grams of any macronutrient, either between groups or within them[9]. Lean body mass, total body water and percentage body fat did not change significantly in either group either, although fat mass did fall in the 5-HTP group and the between-group difference reached significance (p = 0.048)[9].

The honest summary is that the appetite findings are real but were generated at doses several times higher than most people take, and the single trial conducted at 100 mg did not reproduce the food-intake effect. Capsule strength is not a detail to skim past when deciding what a trial result means for you.

Frequently Asked Questions

Has 5-HTP ever failed to beat placebo in a trial?

Yes, and in the largest and most recent one. A 166-patient multicentre randomised crossover trial giving 100 mg twice daily for eight weeks found no difference from placebo in fatigue, depression, anxiety or stress scores, even though it confirmed that serum 5-HTP and serotonin had risen significantly[4]. Publication bias, where trials that find nothing are less likely to be published, means the older literature probably overstates the average effect[5].

How big were the study samples showing 5-HTP beat placebo?

Small. When a Cochrane review applied standard quality criteria to the depression literature it screened 108 studies and found only two admissible ones, covering 64 patients in total[1]. The positive appetite trials enrolled 19[6], 20[7] and 27[8] participants respectively, which limits how confidently any of it generalises.

Does beating placebo in a small trial mean 5-HTP will work for me?

Not necessarily. Group-level statistical significance in a small trial doesn’t guarantee an individual response, and dose matters: the positive appetite trials used 900 mg per day[7] or about 8 mg per kilogram of body weight[6], well above the 50 mg to 200 mg capsules sold at retail.

References

  1. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews, 2002
  2. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutrition Reviews, 2020
  3. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian Journal of Psychiatry, 2013
  4. Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial. Gastroenterology, 2022
  5. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Australian and New Zealand Journal of Psychiatry, 2002
  6. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. Journal of Neural Transmission, 1989
  7. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. American Journal of Clinical Nutrition, 1992
  8. Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation. International Journal of Obesity, 2009
  9. The Effects of 5-HTP on Body Composition: An 8-Week Preliminary RCT. Journal of Dietary Supplements, 2023

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.

Found this useful? Send it to someone who needs it.
Scroll to Top
© 2026 5-HTPHub  |  Health Disclaimer  |  Affiliate Disclosure  |  Privacy Policy  |  Terms  |  About
As an Amazon Associate we earn from qualifying purchases.